Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT

Summary

The aim of the study is to evaluate the adverse events and the efficacy of virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT) performed at the Transplant Clinical Unit of the IRCCS G. Gaslini Institute (IGG).

Timeline

Start

2024-02-27

Primary completion

2024-07-25

Completion

2025-07-25

Drugs

Indications